A high court in India announced Tuesday that it has dismissed petitions against the Competition Commission of India filed by the Indian units of Nissan Motors and Hyundai Motor in efforts to fight a competition probe into the auto industry.
Reports say the Madras High Court dismissed the petitions against the CCI, denying claims by the car companies that the regulator is unfairly investigating the firms and that it did not offer the companies adequate opportunity for oral hearings regarding the matter.
The CCI opened an investigation into several car manufacturers following a complaint issued in 2011 accusing Fiat, Honda Siel and Volkswagen of dominance abuse and other anticompetitive behavior. After a preliminary investigation, the CCI decided to investigate all industry players on suspicion that anticompetitive practices could be used throughout the market.
Specifically, the authority probed dealership launches, spare part sales and after sales services, among other areas of the industry.
In its petition, Nissan argued that it had only launched operations just six months prior to the 2011 complaint and had only a small fraction of the market share between 2010 and 2011, at .52 percent.
The CCI is investigating 17 auto makers as part of the case.
The Madras High Court said Nissan and Hyundai could appeal to the Competition Appellate Tribunal.
Full content: Business Standard
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Federal Court to Hear Case on Trump’s Firing of FTC Democrats
May 20, 2025 by
CPI
UK Government Suffers Third Successive Defeat on Data (Use and Access) Bill
May 20, 2025 by
CPI
Sex Toy Retailer Says Google Breaches EU Digital Market Rules
May 20, 2025 by
CPI
Latham & Watkins Expands Brussels Antitrust Team
May 20, 2025 by
CPI
Brazil’s Antitrust Watchdog Expected to Approve Pet Retail Merger Without Conditions
May 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas